Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662610 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
A Phase 1 study, sponsored by NicOx.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00662610: Completed Phase 1 study, sponsored by NicOx.
NCT00662610 is a Phase 1 study that has completed, run by NicOx. The registered enrollment target is 120 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00662610, a Phase 1 study, has completed, sponsored by NicOx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
Interventions
- DRUG naproxcinod 375 mg -750 mg -1125 mg bid
- DRUG naproxen 250 mg - 500mg -750 mg bid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
What the finished NCT00662610 record still lists
NCT00662610 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 2 interventions - of which naproxcinod 375 mg -750 mg -1125 mg bid is the first listed.
NCT00662610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00662610 about?
NCT00662610 is a clinical study titled "A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure". To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
What is the current status of trial NCT00662610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2008-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00662610?
The interventions under investigation include: naproxcinod 375 mg -750 mg -1125 mg bid (DRUG), naproxen 250 mg - 500mg -750 mg bid (DRUG).
Who is sponsoring clinical trial NCT00662610?
This trial is sponsored by NicOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00662610's enrollment target sits among peer trials
120 479th of 2000 higher than 1,503 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia